FDA Approves Frontline Daratumumab Regimen for Transplant-Eligible Myeloma

Sep 26, 2019 – The FDA has approved daratumumab in combination with bortezomib, thalidomide, and dexamethasone (VTd) for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). The approval is based on results from part 1 of the phase III CASSIOPEIA (MMY3006) study, in which the stringent complete response (sCR) rate at post-consolidation therapy was 29% in patients who received … (leggi tutto)